JAK Libs

1.	Proper Noun
2.	Adjective
3.	Noun
4.	Adjective
5.	Noun
6.	Adjective
7.	Adjective
8.	Noun
9.	Verb - Past Tense
10.	Adjective
11.	Adjective
12.	Adjective
13.	Noun
14.	Verb - Past Tense
15.	Noun
16.	Noun
17.	Adjective
18.	Adjective
19.	Noun
20.	Adjective
21.	Verb - Past Participle
22.	Adjective
23.	Noun

24.	Noun
25.	Verb - Past Tense
26.	Adjective
27.	Adjective
28.	Noun
29.	Verb - Base Form
30.	Adjective
31.	Proper Noun
32.	Noun
33.	Noun
34.	Adjective

JAK Libs

Eli Lilly and Company and <u>Proper Noun</u> Corporation today announced positive topline results of RA-BEAM, the <u>Adjective</u> successful Phase 3 study of baricitinib, an investigational <u>Noun</u> for patients with moderately-to-severely active rheumatoid arthritis.

The study met its <u>Adjective</u> objective of demonstrating superiority compared to <u>Noun</u> after 12 weeks of treatment based on ACR20 response - a <u>Adjective</u> clinical measure that represents at least a 20 percent improvement in RA disease activity. Baricitinib was also <u>Adjective</u> to <u>Noun</u> on key secondary objectives of ACR20 response and improvement in DAS28-hsCRP score after 12 weeks of treatment. Following 24 weeks of treatment, baricitinib <u>Verb - Past Tense</u> <u>Adjective</u> to placebo in preventing progressive radiographic structural <u>Adjective</u> damage. These treatment benefits with baricitinib observed at 12 and 24 <u>Adjective</u> were maintained through 52 weeks of <u>Noun</u>.

<u>Verb - Past Tense</u> to placebo, <u>Noun</u> <u>Noun</u> events rates were similar for baricitinib and <u>Adjective</u> for adalimumab; serious infection rates were <u>Adjective</u> across groups. There were no cases of <u>Noun</u> perforations. One event of tuberculosis was reported in each of the baricitinib and adalimumab groups. Rates of treatment-emergent <u>Adjective</u> events, including infections, were higher for baricitinib and adalimumab <u>Verb - Past Participle</u> to placebo. The most <u>Adjective</u> adverse events observed with baricitinib were <u>Noun</u> and <u>Noun</u>. Discontinuations due to adverse events with similar frequency across treatment groups. A <u>Adjective</u> majority of patients completing this trial

opted to participate in a <u>Adjective</u> extension <u>Noun</u>.

superior in improving signs and symptoms of rheumatoid arthritis compared to the current injectable standard of

care," said ______ Ricks, Lilly senior vice president, and ______, Lilly Bio-Medicines. "If

approved, baricitinib could help <u>Noun</u> expectations for people living with this <u>Adjective</u> disease

©2025 WordBlanks.com · All Rights Reserved.

."